Roles and detection of tissue factor positive microparticle in tumor

doi:10.3760/cma.j.issn.1673-422X.2015.07.013

Abstract

Abstract: Tissue factor positive microparticle (TFMP) plays an important role in the invasion and metastasis of tumor by promoting the formation of the vessels around the tumor. At present a number of studies suggest that TFMP is associated with thrombosis in tumor, but the relevant mechanism is still not fully clear. TFMP is extremely important for the prevention of tumor progression and thrombosis.

Key words: Neoplasms, Venous thrombosis, Thromboplastin, Microparticle

Li Huiqiao, ZhangYuhui. Roles and detection of tissue factor positive microparticle in tumor[J]. Journal of International Oncology, 2015, 42(7): 525-528.

References

［1］ Castellana D, Kunzelmann C, Freyssinet JM. Pathophysiologic significance of procoagulant microvesicles in cancer disease and progression［J］. Hamostaseologie, 2009, 29(1): 51-57. ［2］ Khorana AA, Francis CW, Culakova E, et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy［J］. J Thromb Haemost, 2007, 5(3): 632-634. ［3］ Castellana D, Toti F, Freyssinet JM. Membrane microvesicles: macromessengers in cancer disease and progression［J］. Thromb Res, 2010, 125 Suppl 2: S84-88. ［4］ Hargett LA, Bauer NN. On the origin of microparticles: from "platelet dust" to mediators of intercellular communication［J］. Pulm Circ, 2013, 3(2): 329-340. ［5］ Leroyer AS, Tedgui A, Boulanger CM. Role of microparticles in atherothrombosis［J］. J Intern Med, 2008, 263(5): 528-537. ［6］ Thaler J, Ay C, Pabinger I. Clinical significance of circulating microparticles for venous thromboembolism in cancer patients［J］. Hamostaseologie, 2012, 32(2): 127-131. ［7］ Aharon A, Brenner B. Microparticles, thrombosis and cancer［J］. Best Pract Res Clin Haematol, 2009, 22(1): 61-69. ［8］ Zwicker JI, Trenor CC 3rd, Furie BC, et al. Tissue factorbearing microparticles and thrombus formation［J］. Arterioscler Thromb Vasc Biol, 2011, 31(4): 728-733. ［9］ Yu YJ, Hou XD, Li YM. Effect of tissue factor knockdown on the growth, invasion, chemoresistance and apoptosis of human gastric cancer cells［J］. Exp Ther Med, 2014, 7(5): 1376-1382. ［10］ Vignoli A, Giaccherini C, Marchetti M, et al. Tissue factor expression on platelet surface during preparation and storage of platelet concentrates［J］. Transfus Med Hemother, 2013, 40(2): 126-132. ［11］ Rauch U, Bonderman D, Bohrmann B, et al. Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor［J］. Blood, 2000, 96(1): 170-175. ［12］ Zhou L, Qi XL, Xu MX, et al. Microparticles: new light shed on the understanding of venous thromboembolism［J］. Acta Pharmacol Sin, 2014, 35(9): 1103-1110. ［13］ Zwicker JI, Liebman HA, Neuberg D, et al. Tumorderived tissue factorbearing microparticles are associated with venous thromboembolic events in malignancy［J］. Clin Cancer Res, 2009, 15(22): 6830-6840. ［14］ Zwicker JI. Predictive value of tissue factor bearing microparticles in cancer associated thrombosis［J］. Thromb Res, 2010, 125 Suppl 2: S89-91. ［15］ Voloshin T, Fremder E, Shaked Y. Small but mighty: microparticles as mediators of tumor progression［J］. Cancer Microenviron, 2014, 7(12): 11-21. ［16］ AlNedawi K, Meehan B, Micallef J, et al. Intercellular transfer of the oncogenic receptor EGFRⅧ by microvesicles derived from tumour cells ［J］. Nat Cell Biol, 2008, 10(5): 619-624. ［17］ Tesselaar ME, Romijn FP, Van Der Linden IK, et al. Microparticleassociated tissue factor activity: a link between cancer and thrombosis?［J］. J Thromb Haemost, 2007, 5(3): 520-527. ［18］ Tesselaar ME, Romijn FP, Van Der Linden IK, et al. Microparticleassociated tissue factor activity in cancer patients with and without thrombosis［J］. J Thromb Haemost, 2009, 7(8): 1421-1423. ［19］ Thomas GM, PanicotDubois L, Lacroix R, et al. Cancer cellderived microparticles bearing Pselectin glycoprotein ligand 1 accelerate thrombus formation in vivo［J］. J Exp Med, 2009, 206(9): 1913-1927. ［20］ Khorana AA, Francis CW, Menzies KE, et al. Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer［J］. J Thromb Haemost, 2008, 6(11): 1983-1985. ［21］ Manly DA, Wang J, Glover SL, et al. Increased microparticle tissue factor activity in cancer patients with venous thromboembolism［J］. Thromb Res, 2010, 125(6): 511-512. ［22］ Key NS, Chantrathammachart P, Moody PW, et al. Membrane microparticles in VTE and cancer［J］. Thromb Res, 2010, 125 Suppl 2: S80-83. ［23］ Lacroix R, Robert S, Poncelet P, et al. Overcoming limitations of microparticle measurement by flow cytometry［J］. Semin Thromb Hemost, 2010, 36(8): 807-818.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying. Research progress of habitat analysis in radiomics of malignant tumors [J]. Journal of International Oncology, 2024, 51(5): 292-297.